Neuralstem Plans Deep Dive Into Failed Phase II Major Depression Trial
Executive Summary
Failure of NSI-189 in major depression study sends stock price down about 50% and next steps for development are unclear.
You may also be interested in...
Neuralstem's ALS therapy works in 'subset' of patients
Neuralstem is moving forward with development of its spinal cord-derived stem cell treatment for patients with amyotrophic lateral sclerosis (ALS) following mostly positive Phase II results for the product.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.